Related by context. All words. (Click for frequent words.) 72 Testosterone MDTS R 70 Testosterone MDTS ® 69 Luramist TM 67 Hypoactive Sexual Desire Disorder 65 systemic Phase 1b 65 Custirsen 65 CDAD Clostridium difficile 64 Randomized Double blind 64 Second Pivotal Phase 64 inflammatory PDE 64 Investigational Treatment 63 Randomized Double Blind 63 Capsulitis 63 Phase III Pivotal 63 Pivotal Phase 63 6 sulfatase 63 Randomized Phase 63 Meets Primary Endpoint 63 Phase 2b Clinical Trial 63 Telik Announces 63 YOUR LOCAL ANIMAL SHELTER 62 Pooled Analysis 62 Elestrin ® 62 CYT# potent vascular disrupting 62 AN# topical anti 62 Oral Fingolimod 62 pralatrexate injection folate analogue 62 Frozen Shoulder syndrome Adhesive 62 avanafil PDE5 inhibitor 62 Treatment Naive Patients 62 Phase III Clinical Trial 62 R#/MEM # 62 EXECUTIVE SUMMARY II 61 evaluating mipomersen 61 CG# oncolytic virus 61 Empatic ™ 61 recombinant PSMA vaccine 61 Phase 2b Trial 61 Crofelemer budesonide foam 61 pulmonology portfolio 61 LUX Lung 61 evaluating tesamorelin 61 Study Evaluating 61 BENLYSTA TM 61 non constipating irritable 61 PREGNANT PROCHIEVE ® 61 OAB overactive bladder 61 Initiate Phase 61 PEGINTRON TM 61 Study Shows Promise 61 Placebo Controlled 61 Truvada tablets 61 HCD# [002] 61 allosteric modulator PAM 61 VIVITROL ® 60 Randomized Phase II 60 Perifosine KRX 60 Bayer HealthCare Onyx Pharmaceuticals 60 First Patient Dosed 60 Sapacitabine 60 EOquin TM phase 60 lintuzumab SGN 60 Syncria albiglutide 60 drug pipeline TAFA# 60 novel orally inhaled 60 albiglutide currently 60 Hormone Receptor Positive 60 Treatment Shows Promise 60 overactive bladder AA# 60 complement inhibitor eculizumab 60 Desvenlafaxine Succinate 60 Dose Escalation 60 Successfully Completes Phase 60 Phase III PREGNANT PROCHIEVE 60 recurrent glioma 60 ORAL Solo 60 dependent kinase inhibitor 60 Gene Mutation Linked 60 Mylan Receives Approval 60 approved incretin mimetic 60 Completes Patient Enrollment 60 BLOOM Behavioral modification 60 Dupuytren Disease 60 Treatment Experienced 60 Complicated Skin 60 ELADUR ™ 60 comparing alemtuzumab 60 Phase IIb Trial 60 humanized interleukin 6 60 blinded randomized placebo controlled 60 Initiated Phase 59 Mg Usa 59 INSPIRE Trial Phase III 59 Shows Promise Against 59 dimebon latrepirdine 59 ADVANCE ILLUMINATE 59 Oral Calcitonin 59 Confirmatory Phase 59 See CLINICAL PHARMACOLOGY 59 intravesical infusion therapy 59 Relapsed Multiple Myeloma 59 LymphoStat B belimumab 59 Demonstrates Positive 59 Trial Evaluating 59 malignant mesothelioma Alfacell 59 Initiate Phase III 59 recurrent metastatic ovarian cancer 59 cardiac myosin activator omecamtiv 59 First Patient Enrolled 59 JAK2 Inhibitor 59 Advanced Melanoma 59 BCG refractory carcinoma 59 Rare Genetic 59 Naive Patients 59 myocardial infarction ventricular fibrillation 59 Relapsing Multiple Sclerosis 59 REVIVE TA 59 MKC# 59 novel VDA molecule 59 Synta Announces 59 number NCT# ClinicalTrials.gov 59 TRANSDUR ™ 59 Agonist MABA program 59 Phase 2a Clinical Trial 59 opioid bowel dysfunction 59 acute peptic ulcer 59 lead Aganocide compound 59 ® chorionic gonadotropin 59 CYP#A# CYP#D# 59 Phase 2a Trial 59 Renal Impairment 59 Phase III Clinical Trials 59 Malignant Glioma 58 Gabapentin GR TM 58 Subgroup Analysis 58 OMP #R# 58 II Clinical Trial 58 personalized cellular immunotherapy 58 XL# anticancer compounds 58 Relapsing Remitting Multiple Sclerosis 58 Ozarelix 58 MKC# MT 58 Amigal TM 58 receiving chemoradiation therapy 58 Aeolus Pharmaceuticals Announces 58 Randomized Controlled 58 modified glutathione analog 58 acyclovir Lauriad R 58 Peginterferon Alfa 2a 58 acute mania 58 Prolongs Survival 58 Cetrorelix 58 treatment naive genotype 58 See CONTRAINDICATIONS 58 Suppository Hydrocortisone Acetate Rectal 58 individualized cellular immunotherapy 58 Multicenter Randomized 58 Dose Ranging 58 Initiates Phase 58 Patient Enrollment 58 Clinical Trial Evaluating 58 mecarbil 58 VICTOR E1 58 budesonide foam 58 treatment naïve genotype 58 hGH CTP Phase 58 Blind Placebo Controlled Trial 58 Completes Enrollment 58 MEK Inhibitor 58 solid tumors ZYBRESTAT 58 EnteroMedics proprietary neuroblocking technology 58 VICTOR E3 58 Therapy Improves 58 CATIE AD 58 delivers fluocinolone acetonide FA 58 pseudobulbar affect PBA 58 Drug Prevents 58 Elagolix 58 ACTEMRA TM 58 Cutaneous T 58 FOLOTYN ® 58 Ocrelizumab 58 NEBIDO VANTAS SUPPRELIN LA 58 Vitrasert R 58 Combination Treatment 58 HCV NS5B polymerase 58 Phase 1b Clinical Trial 58 Multicenter Phase 58 oral dual endothelin 58 Submits NDA 58 candidates Augment ™ 58 Qnexa TM 58 Systemic Sclerosis 58 influenza BCX# purine nucleoside 58 Phase IIb Clinical Trial 58 humanized therapeutic 58 keloid scarring 58 Cerebril TM 58 R lenalidomide 58 Silodosin 58 investigational oral inhibitor 58 brand ciclesonide HFA 58 EQUATE OB 58 TRACON Pharmaceuticals Inc. 58 Single Dose 58 visilizumab 58 Slow Progression 58 C1 INH deficiency 58 Drug Shows Promise 57 Novel Oral 57 class mGluR5 inhibitor 57 Adjuvant Treatment 57 Rigel R# 57 Patients Suffering 57 Multiple Ascending Dose 57 Phase 2b Study 57 Appears Safe 57 STRIDE PD 57 Diabetic Macular Edema 57 Recurrent Glioblastoma 57 forodesine purine nucleoside phosphorylase 57 Prospective Randomized 57 Clot Busting 57 D aspartate NMDA receptor 57 sodium thiosulfate STS 57 Decompensated Heart Failure 57 Telik logo TELINTRA 57 Effectively Treats 57 Protease Inhibitor 57 candidate REP# 57 Relapsed Refractory 57 DIRECT Trial 57 Pivotal Phase III 57 HCV SPRINT 57 Multicenter Randomized Double 57 product platforms AZX# 57 Phase Ib IIa 57 opioid naive 57 By JENNIFER LEARN 57 PREGNANT PROCHIEVE Extending GestatioN 57 clinical trials Archexin 57 Phase IIa Clinical Trial 57 Cardiac Resynchronization 57 Cerebral Amyloid Angiopathy 57 VEGFR2 inhibitor 57 Dementia Related Psychosis 57 Zenvia ™ 57 Initiates Phase III 57 oncolytic virus therapies 57 NS5B polymerase 57 REVIVE Diabetes 57 Hormone Refractory Prostate Cancer 57 Ovitrelle R Serostim 57 Chronic Heart Failure 57 Initiates Enrollment 57 dose escalation phase 57 Refractory Peripheral T 57 hypertrichosis occurred 57 MKC# MKC# PP 57 Acute Decompensated Heart Failure 57 pharmacogenomic translational research 57 Pulmonary Arterial Hypertension 57 evaluating Actimmune 57 evaluating satraplatin plus 57 Renal Cell Carcinoma 57 develop HBV reactivation 57 Initiates Phase II 57 Eszopiclone 57 Refractory Angina 57 induced macular edema 57 AAG geldanamycin analog 57 Refractory Hodgkin Lymphoma 57 Lymphocytic 57 Slows Progression 57 Limb Ischemia 57 Efficacy Trial 57 Dose Ranging Study 57 Hedgehog Pathway Inhibitor 57 dextromethorphan quinidine 57 ATRA IV 57 TMC# C# 57 GRNOPC1 contains 57 opioid induced bowel dysfunction 57 Granted Orphan Drug 57 agonistic human 57 Soft Tissue Sarcoma 57 oral prodrug 57 Metastatic Prostate Cancer 57 AVN# Phase 57 CYP#A# isoenzyme 57 oral nucleoside analogue 57 attention-deficit/hyperactivity 57 non nucleoside HCV 57 Controlled Trial 57 HGS ETR1 mapatumumab 57 IND Filing 57 Plaque Psoriasis 57 candidate XP# 57 TM pralatrexate injection 56 Metastatic Renal Cell Carcinoma 56 atypical Hemolytic Uremic Syndrome 56 Phase Ib Clinical Trial 56 relapsed refractory multiple myeloma 56 Controlled Study 56 Monotherapy 56 Neovascular Age Related Macular 56 Improves Outcomes 56 oral calcitonin licensed 56 Clinical Trial Results 56 catheter occlusion 56 hyperplasia BPH 56 PEGINTRON REBETOL combination 56 Peginterferon alfa 2b 56 Demonstrates Efficacy 56 Commences Phase 56 administering VIVITROL 56 particularly SANCTURA XR 56 anti VEGF aptamer 56 NDA Submission 56 TRANSDUR ® 56 receiving INTRON 56 Newly Diagnosed Multiple Myeloma 56 Glufosfamide 56 oral ghrelin agonist 56 Non Alcoholic Steatohepatitis 56 dyskinesia PD LID 56 Fibrillex TM 56 CYP#A# substrate 56 mGluR5 NAM 56 Spinal Fractures 56 Vicriviroc 56 carcinoma mCRC 56 GATTEX ® 56 Coadministration 56 Aflibercept 56 Treatment Resistant 56 AEG# 56 Hsp# Inhibitor 56 Heterozygous Familial Hypercholesterolemia 56 Empatic TM 56 Demonstrates Sustained 56 kidney urologic 56 Metastatic Melanoma 56 RANK Ligand inhibitor 56 Publicist Charlie Sheen 56 Initiates Clinical Trial 56 Degarelix 56 CCR5 mAb 56 transmucosal delivery system 56 Advanced Renal Cell 56 refractory cutaneous T 56 Acute Exacerbations 56 Kit CD# positive 56 including eniluracil ADH 56 novel antimitotic agent 56 TELINTRA R 56 AZX# Phase 56 designated HVTN 56 Myelofibrosis 56 IMPACT DCM 56 myelodysplastic myeloproliferative diseases 56 Ribavirin causes 56 forodesine 56 Brentuximab Vedotin SGN 56 monoclonal antibody IgG1 Mab 56 initiate multicenter 56 Pharmacokinetic Study 56 Oral NKTR 56 plus Copegus R 56 J Am Acad 56 NMT Medical Announces 56 Hemispherx flagship products 56 Shows Efficacy 56 oral Janus kinase 56 Central Retinal Vein 56 mGluR5 negative 56 phase Ib 56 Tanespimycin 56 LibiGel Phase III 56 Pruvel TM 56 NicVAX TM 56 Pivotal Trial 56 refractory chronic lymphocytic 56 Chronic Hepatitis C 56 non nucleoside inhibitor 56 Amgen Neulasta R 56 Relapse Prevention 55 apricitabine ATC 55 Phase #b/#a clinical 55 RCW Breast Cancer 55 Ophena TM 55 SPEAR Study 55 registrational trial 55 undergoing elective percutaneous 55 Severe Sepsis 55 immunosuppressive compound 55 Intracranial Aneurysms 55 PharmacoSurgery TM platform 55 severe oral mucositis 55 TKB# 55 Combination REOLYSIN R 55 BRIM2 55 relapsed MM 55 HDAC Inhibitor 55 PEGylated docetaxel 55 Pharmacokinetics PK 55 evaluating picoplatin 55 systemic anaplastic large 55 dasatinib Sprycel ® 55 SPRYCEL ® 55 STEALTH C 55 Schizophrenics Anonymous 55 cladribine Cladribine Tablets 55 includes TOLAMBA TM 55 Trial Issue www.emagazine.com 55 Aurora Kinase 55 SUPPRELIN R LA 55 telomerase therapeutic 55 Exelixis XL# 55 bone marrow reticulin deposition 55 retinal vein occlusion induced 55 RhuDex 55 MAGE A3 ASCI 55 Teva Provides Update 55 Submits Biologics License Application 55 cetrorelix pamoate 55 CCX# B 55 Onyx Pharmaceuticals Announces 55 Castration Resistant Prostate Cancer 55 Androxal TM 55 metastatic hormone refractory 55 herpetic keratitis 55 unique alkylating agent 55 OPT CHF 55 Alzheimer disease cognitive impairment 55 CDK cyclin dependent 55 damage cirrhosis liver 55 bapineuzumab AAB 55 Hypertensive Patients 55 Recurrent Breast Cancer 55 albiglutide 55 Antigen Specific 55 EXPLORE Xa 55 Adjuvant Chemotherapy 55 Tyrosine Kinase Inhibitor 55 Syncria R 55 3 registrational trial 55 Pegloticase 55 SPL# Gel vaginal microbicide 55 COSIRA trial 55 Genasense oblimersen sodium Injection 55 SSRI SNRI 55 Anturol TM 55 Co Occurring 55 ZYBRESTAT fosbretabulin 55 data management Clintrial 55 HHS Substance Abuse 55 FDA APPROVES 55 placebo controlled Phase 55 d l leucovorin 55 R#/MEM 55 HCV RESPOND 2 55 known dihydropyrimidine dehydrogenase 55 IIa clinical 55 Achieves Primary Endpoint 55 Patients Treated With 55 Daclizumab 55 de novo kidney transplant 55 Intervention Effectiveness 55 Aplidin R 55 NASH Huntington 55 Enrolling Patients 55 R roscovitine CDK cyclin 55 IIa Clinical Trial 55 Enzastaurin 55 Atypical Hemolytic Uremic Syndrome 55 evaluating carfilzomib 55 diabetic peripheral neuropathic DPN 55 steroid refractory ulcerative 55 alvespimycin 55 Primary Hypercholesterolemia 55 HER2 Positive 54 Evaluation Program CTEP 54 consultation Duber 54 Aryplase 54 relapsing remitting MS RRMS 54 APEX PD 54 accompanying electrolyte abnormalities 54 hypothyroidism hyperglycemia hypotension arrhythmihemorrhagic colitis development 54 Preclinical Models 54 ® lenalidomide 54 refractory NSCLC 54 Phase IIa trials 54 NCCN Updates 54 Begins Dosing 54 unresectable Stage III 54 Phase 1b clinical trials 54 evaluating T DM1 54 Dose Limiting Toxicity DLT 54 Forodesine HCl 54 Pivotal Study 54 Uterine Fibroid Embolization 54 assessing T DM1 54 steroid refractory GvHD 54 CTA# Injection 54 PF # [002] 54 R tiagabine hydrochloride NUVIGIL 54 Pimavanserin 54 bile duct tumor 54 Long Term Efficacy 54 See WARNINGS 54 next generation URAT1 54 Physician Insights 54 ALN VSP Phase 54 ENABLE Phase 2 54 Metastatic Colorectal Cancer 54 RELOVAIR ™ 54 Microplasmin 54 Antitumor Activity 54 treat benign prostatic 54 JZP 54 Shows Promising 54 Prostate AdenoCarcinoma Treatment 54 moderate hepatic impairment 54 targeted radiotherapeutic 54 BRIM3 54 Prednisone Against Refractory 54 DDP# 54 GOUT 54 Phase Ib clinical trials 54 R ferumoxytol Injection 54 Leukemias 54 non splenectomized 54 signal detection CTSD 54 CML CP 54 Previously Treated 54 Personalized Immunotherapy 54 virus HCV protease inhibitor 54 Chronic Myeloid Leukemia 54 included exfoliative dermatitis 54 R Saizen R 54 placebo controlled dose escalation 54 evaluating Xcytrin 54 INTEGRILIN R eptifibatide Injection 54 receptor tyrosine kinase inhibitor 54 via intradermal injections 54 Bezielle 54 PRTX 54 Hepatocellular Carcinoma HCC 54 evaluating tivozanib 54 Phase III Trial 54 Callisto initiated 54 generation PNP inhibitor 54 relapsed Acute Myeloid 54 ragweed allergy immunotherapeutic 54 adjuvant GIST 54 Receives Orphan Drug Designation 54 PLK1 SNALP 54 non thiazolidinedione TZD 54 Presents Positive 54 mania hypomania 54 PEGylated Fab fragment 54 post herpetic neuralgia PHN 54 Proellex TM 54 novel tubulin binding 54 Heart Failure Patients 54 Anti Tumor Activity 54 Motesanib 54 Immunotherapeutic 54 NU# direct 54 evaluating intravenous picoplatin 54 phase III isavuconazole 54 Overactive Bladder OAB 54 cutaneous T 54 REG2 54 R sorafenib tablets 54 evaluate ZFP Therapeutic 54 depression schizophrenia bipolar 54 compound INCB# 54 Epratuzumab 54 COPEGUS R 54 Non Alcoholic Fatty 54 FDA Accepts 54 Eniluracil 54 GLUMETZA R 54 Chronic Lymphocytic Leukemia 54 Phase IIIb 54 CHAMPION PCI 54 Anti Tumor 54 Phase III placebo controlled 53 confirmatory Phase 3 53 Paroxysmal Atrial Fibrillation 53 elotuzumab 53 selective androgen receptor modulator 53 LymphoStat B TM 53 recurrent glioblastoma multiforme 53 Traficet EN 53 biliary tract cancer 53 LUMINATE 53 intravenous RSD# 53 novel chimeric natriuretic 53 Phase III Trials 53 Dapagliflozin 53 Initiates Clinical 53 Romidepsin 53 Proc Am Soc 53 TNF Tumor Necrosis Factor 53 investigational monoclonal antibody 53 Bosutinib 53 HepeX B TM 53 PEGylated interferon beta 1a 53 + Perifosine Evaluation 53 sarcoma melanoma 53 novel histone deacetylase 53 CEQ# 53 Annamycin 53 Al-Anon/Alateen meetings 53 evaluating pirfenidone 53 registrational Phase 53 naïve HCV 53 CINQUIL 53 Prodarsan 53 blinded placebo controlled 53 tramiprosate Alzhemed TM 53 Commence Phase 53 Albuferon Phase 53 angiotensin analog 53 Phase 2a clinical 53 Hematology Molecular Pathology 53 Previously Untreated 53 Comorbid 53 Randomized Study 53 rALLy clinical trial 53 ® bortezomib 53 Efficacy Results 53 PNP inhibitor 53 Substance Use 53 placebo controlled clinical 53 interferon beta 1a infertility 53 mertansine 53 alfa 2a 53 MEND CABG 53 Pruvel ™ prulifloxacin 53 IgG1 monoclonal antibody 53 SinuNase TM 53 ThermoDox ® clinical 53 candidates Azedra TM 53 Ofatumumab 53 Files IND 53 ALSYMPCA 53 orally administered inhibitor 53 phase IIb trial 53 PEG PAL 53 interferon gamma 1b 53 Allovectin 7 R 53 Plicera 53 Non Invasive Treatment 53 Exherin TM 53 oropharyngeal candidiasis OPC 53 Denufosol 53 worsening thrombocytopenia 53 LibiGel testosterone gel 53 multicenter Phase 53 controlled multicenter 53 Hepatocellular Carcinoma 53 metastatic colorectal carcinoma 53 initiated Phase Ib 53 Node Positive 53 ARRY # 53 Phase Ib clinical 53 Omacetaxine 53 dacetuzumab SGN 53 Vidaza ® 53 relapsing multiple sclerosis 53 ENESTnd 53 QNEXA ® 53 Archexin 53 cancer neuroendocrine tumor 53 unresectable stage 53 Phase IIA 53 IMPDH inhibitor 53 XL# SAR# 53 Pivotal Phase II 53 CIMZIA TM certolizumab pegol 53 Myelodysplastic Syndrome MDS 53 DEB# 53 sapacitabine CYC# 53 Ispinesib SB # 53 GVAX ® 53 PROACT Phase 2 53 Receives Approvable Letter 53 Therapy Reduces 53 IMPACT DCM trial 53 PRE SURGE 53 CONQUER OB 53 EQUIP OB 53 GSK# [001] 53 Intravitreal 53 PRECiSE 53 schizophrenia schizoaffective disorder 53 MERLIN TIMI 53 erlotinib Tarceva ® 53 metastatic colorectal 53 TNFerade ™ 53 omacetaxine mepesuccinate 53 Gabapentin GR 53 Dacogen injection 52 sunitinib Sutent ® 52 ERBITUX cetuximab 52 IL# PE#QQR 52 trial evaluating Prochymal 52 Glycopyrrolate 52 biologic antibody 52 Novel Inhibitor 52 controlled multicenter Phase 52 Philadelphia Chromosome Positive 52 Acetavance TM intravenous acetaminophen 52 CEL SCI Phase III 52 Improves Survival 52 LUNESTA TM 52 elderly myelodysplastic syndromes 52 phase IIb study 52 PRX # 52 Completes Patient Enrolment 52 Tumor Response 52 JunJing II 52 Dose Finding 52 EDEMA3 52 AVOREN 52 initiated confirmatory Phase 52 Liraglutide Effect 52 Hodgkin lymphoma HL 52 interferon alpha IFN 52 Jury Selection Resumes 52 pediatric Crohn disease 52 arsenic trioxide injection GABITRIL 52 Sanja Amaj 52 Safinamide 52 Phase IIb randomized 52 generation URAT1 inhibitor 52 TLK# 52 multicenter dose escalation 52 Ceflatonin R 52 multicenter randomized placebo controlled 52 ONCONASE R 52 stage IIIb IV 52 Picoplatin Efficacy After 52 IMiDs R 52 Aggressive Reduction 52 ZOLINZA 52 PrevOnco ™ 52 PRECISE Trial 52 TO AVOID PREGNANCY WHILE 52 Fx #A 52 Contrast Echocardiography 52 Cannabinor 52 Phenoptin 52 CAPACITY trials 52 Shows Statistically Significant 52 CAMMS# 52 Glatiramer Acetate 52 Ovarian Cancers 52 FUSILEV enhances 52 TMC# [002] 52 IN PATIENTS WITH 52 imetelstat GRN#L 52 THAT ARE DIFFICULT TO 52 examining REOLYSIN 52 LUVENIQ 52 Pivotal Clinical Trial 52 ACAPODENE 52 pan histone deacetylase 52 HER2 Positive Breast Cancer 52 arsenic trioxide injection 52 Xcytrin R 52 occlusion PAO 52 Apaziquone 52 Corlux 52 RSD# oral 52 TACI Ig 52 R vitespen 52 Phase 2b clinical 52 GetGoal Phase III 52 Forodesine 52 Phase 2a trial 52 Lenocta TM 52 clinical trials SGN 52 Horizant ™ 52 Parkinson disease levodopa induced 52 Unresectable 52 PDX pralatrexate 52 injectable enzyme 52 Advaxis Phase 52 Randomised 52 multicenter Phase III 52 Initiates Phase 2b 52 AIR CF2 52 riociguat 52 Antitumor activity 52 ThermoDox R 52 Humanized Anti 52 rALLy 52 TASKi2 52 evaluating bafetinib 52 urocortin 2 52 Diamyd ® 52 PARGLUVA 51 multi kinase inhibitor 51 Anthracycline 51 huN# DM1 51 Conduct Disorder 51 stated Michelle Berrey 51 GALNS 51 CR# vcMMAE 51 Zalypsis 51 R bortezomib 51 metastatic GIST 51 randomized controlled multicenter 51 crack cocaine Lovetere 51 arthritis PsA 51 osteolytic bone disease 51 treat chronic sinusitis 51 IMPACT IMmunotherapy 51 advanced metastatic renal 51 triggers apoptosis programmed 51 injectable suspension GABITRIL 51 sunitinib malate 51 Capesaris 51 docetaxel Taxotere R 51 metastatic androgen independent 51 investigational humanized monoclonal antibody 51 OLpur TM H2H 51 indolent follicular non 51 leukemia AML 51 Carotid Revascularization Endarterectomy vs. 51 Abstract Accepted 51 Randomized phase 51 RECORD1 51 Club Stairways Comprehensive 51 multicenter multinational 51 oral rivaroxaban 51 LHRH receptor positive 51 BENLYSTA ® 51 IMA# 51 investigational pan BCR 51 stage IIIb 51 Sorafenib HCC Assessment 51 ACCLAIM COPD 51 multicenter placebo controlled 51 clinical trials Multikine 51 resistant hormone refractory 51 ZFP Therapeutic 51 SUCCEED trial 51 KRN# 51 benign prostatic hyperplasia enlarged 51 Phase IIb trials 51 PRT# 51 MEND CABG II 51 Phase lll 51 confirmatory pivotal 51 Hypertrophy 51 evaluating satraplatin 51 dosing cohort 51 refractory metastatic 51 antibody MAb 51 Phase IIIb clinical 51 randomized controlled Phase 51 prostate cancer HRPC 51 XL# XL# XL# 51 icatibant 51 Namenda Memantine HCl 51 R roscovitine 51 APTIVUS 51 velafermin 51 Xeloda ® 51 oral calcitonin 51 RESTORE CLI trial 51 oral picoplatin 51 ocrelizumab 51 FOLFOX6 chemotherapy regimen 51 HEPLISAV ™ 51 AIR CF1 51 Maushart admits 51 phase IIa clinical 51 BENLYSTA ™ 51 Interpersonal psychotherapy 51 Therapeutic Efficacy 51 Free apologetics 51 autologous cellular immunotherapy 51 Abdul Bair Ibrahimi 51 metastatic ocular 51 Vicinium TM 51 nilotinib Tasigna ® 51 INCB# [001] 51 multicenter Phase II 51 sexual compulsivity 51 Vascular Disrupting Agent 51 Zemiva ™ 51 Adenoviral 51 Investigational Oral 51 label multicenter Phase 51 HuMax EGFr 51 castration resistant hormone refractory 51 Jury Deliberations Begin 51 baminercept 51 Epothilone D 51 Placebo controlled 51 Paclitaxel Carboplatin 51 GREATER HAMILTON 'S 51 trial evaluating PRX# 51 TG MV 51 phase IIb clinical 51 ADMIRE HF 51 Cell Lymphoma 51 logo HeartMate 51 serum phosphorous 51 Oppositional Defiant Disorder 51 Pemetrexed 51 oral sapacitabine 51 investigational protease inhibitor 51 Quinamed 51 Sipuleucel T 51 KNS # 51 Endologix Powerlink System 51 Phase 2b clinical trials 50 rasagiline tablets 50 PINPOINT TM System 50 Diabetic Macular Edema DME 50 Unstable Angina 50 CB2 selective receptor agonist 50 5 fluorouracil leucovorin 50 AETD VIP abstain 50 PROVENGE sipuleucel T 50 NAMI Casper 50 plus dacarbazine 50 chronic myeloid 50 TBC# 50 Phase Ib II 50 acute PAO 50 Known hypersensitivity 50 TNFerade TM 50 ovarian esophageal 50 cetrorelix 50 Alimentary Tract 50 Ridaforolimus 50 Squamous Cell Carcinoma 50 placebo controlled multicenter 50 Spokeswoman Angela Sekston 50 PrevOnco 50 ascending dose 50 nephropathic cystinosis 50 Zemplar Capsules 50 metastatic castration resistant 50 Phase III ADT 50 Tesetaxel 50 metastatic malignant 50 Curaxin CBLC# 50 Pirfenidone 50 selective modulator 50 PREOS R 50 AeroLEF TM 50 midstage clinical 50 renal failure interstitial lung 50 Matrix Phase 2b 50 Pivotal Trials 50 Anti VEGF 50 mg/m2 cohort 50 BEMA Buprenorphine 50 PRESEPT 50 AETD abstain 50 aflibercept VEGF Trap 50 HCV Genotype 50 dasatinib Sprycel 50 Albuferon TM 50 PROTEGE 50 Solzira ™ 50 Preclinical Study 50 Phase 1b 50 Phase 1a 50 dose escalation clinical 50 comparing XIENCE V 50 placebo controlled Phase III 50 evaluating ASA# 50 Luveniq 50 class anticancer quinolone 50 JAK inhibitor 50 Phase 1a clinical 50 confidential informants linking 50 ADVANCE PD 50 torezolid phosphate 50 recurrent malignant glioma 50 multicenter phase 50 European Sepsis Trial 50 phase Ib clinical 50 oral deforolimus 50 Spiegelmer ® 50 multicentre randomized double 50 confirmatory Phase III 50 anti CTLA